Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 12/06 03:32:09 am
8258.5 GBX   +0.82%
03:29aFTSE 100 gains after choppy week with oil stocks in lead
RE
02:06aCovid-19 Vaccination - Federal Govt Approves Booster Dose
AQ
01:21aPfizer accused of funding anti- AstraZeneca info
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca Sees Positive Results for Enhertu Trial

09/17/2021 | 10:50am EST

By Chris Wack

AstraZeneca and Daiichi Sankyo Co. said they said the saw positive results from a Phase II trial that showed Enhertu provided a clinically meaningful and durable tumor response in patients with HER2-positive metastatic and/or unresectable gastric or gastroesophageal junction adenocarcinoma previously treated with a trastuzumab-containing regimen.

Enhertu fam-trastuzumab deruxtecan-nxki is an HER2-directed antibody drug conjugate intended to treat gastric cancer.

In the primary analysis, the first trial of Enhertu specifically in Western patients with HER2-positive metastatic gastric cancer or GEJ adenocarcinoma, Enhertu demonstrated a confirmed overall response rate of 38% as assessed by independent central review.

Three complete responses and 27 partial responses were observed in patients treated with Enhertu. These results were consistent with those from a previous registrational Phase II trial.

After a median follow-up of 5.7 months, the median duration of response of Enhertu was 8.1 months. The median progression-free survival was 5.5 months. An exploratory endpoint of confirmed disease control rate of 81% was seen.

Enhertu is approved in Israel, Japan and the U.S. for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the trial.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

09-17-21 1250ET

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.82% 8260 Delayed Quote.11.84%
DAIICHI SANKYO COMPANY, LIMITED 0.26% 2846.5 End-of-day quote.-19.48%
All news about ASTRAZENECA PLC
03:29aFTSE 100 gains after choppy week with oil stocks in lead
RE
02:06aCovid-19 Vaccination - Federal Govt Approves Booster Dose
AQ
01:21aPfizer accused of funding anti- AstraZeneca info
AQ
01:00aCOVID shots are finally arriving, but Africa can't get them all into arms
RE
12/05Pfizer Denies Claims of Funding Misinformation Against AstraZeneca's COVID-19 Jab
MT
12/04Covid-19 - Nigeria Approves Booster Doses for Enhanced Protection
AQ
12/03AstraZeneca Explores Listing of Newly-Created Vaccines Unit
MT
12/03AstraZeneca Reportedly Weighs Listing of Newly-Created Vaccines Unit
MT
12/03European Stocks Close Lower After Disappointing US Jobs Data
MT
12/03AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Undersco..
CI
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 919 M - -
Net income 2021 3 423 M - -
Net Debt 2021 25 253 M - -
P/E ratio 2021 36,9x
Yield 2021 2,60%
Capitalization 168 B 168 B -
EV / Sales 2021 5,38x
EV / Sales 2022 4,40x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 108,38 $
Average target price 137,48 $
Spread / Average Target 26,9%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC11.84%167 779
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641